TY - JOUR
T1 - Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005
AU - Durbin, Anna P.
N1 - Funding Information:
I was the Principal Investigator for the live attenuated dengue vaccine trials sponsored by the National Institutes of Health referenced in this article. I do not hold any patent rights to the vaccines. These trials were conducted under a contract between the National Institute of Allergy and Infectious Diseases and Johns Hopkins University.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/8
Y1 - 2020/8
N2 - Dengue is the most important arboviral disease world-wide with an estimated 400 million annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for dengue seropositive individuals aged 9–45 years. There is great need for a dengue vaccine that could be given to dengue-naïve individuals and very young children. To that end, the U.S. NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach evaluating the safety, infectivity, and immunogenicity of different candidates. This approach identified poor candidates who were then discarded from further evaluation. Each of the components of the tetravalent vaccine formulation is able to replicate to very low titer, inducing a homotypic immune response to each. The immune response elicited by the tetravalent vaccine is balanced, without immunodominance of one component. The vaccine was licensed by several manufacturers for development, including the Instituto Butantan which initiated a Phase 3 efficacy trial.
AB - Dengue is the most important arboviral disease world-wide with an estimated 400 million annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for dengue seropositive individuals aged 9–45 years. There is great need for a dengue vaccine that could be given to dengue-naïve individuals and very young children. To that end, the U.S. NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach evaluating the safety, infectivity, and immunogenicity of different candidates. This approach identified poor candidates who were then discarded from further evaluation. Each of the components of the tetravalent vaccine formulation is able to replicate to very low titer, inducing a homotypic immune response to each. The immune response elicited by the tetravalent vaccine is balanced, without immunodominance of one component. The vaccine was licensed by several manufacturers for development, including the Instituto Butantan which initiated a Phase 3 efficacy trial.
UR - http://www.scopus.com/inward/record.url?scp=85093669070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093669070&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2020.09.005
DO - 10.1016/j.coviro.2020.09.005
M3 - Review article
C2 - 33164790
AN - SCOPUS:85093669070
SN - 1879-6257
VL - 43
SP - 79
EP - 87
JO - Current Opinion in Virology
JF - Current Opinion in Virology
ER -